Bayer Stock: Still Under Pressure?

Bayer's stock presents a mixed picture for investors. While occasional daily upticks occur, the dominant trend has been negative, with substantial losses over monthly and yearly periods. The share price remains significantly depressed compared to its 52-week high and struggles below key technical benchmarks like the 50-day and 200-day moving averages.

The company's Q4 2024 results highlighted these difficulties, swinging to a net loss from a profit the previous year, alongside a slight revenue dip. The dividend forecast remains minimal, offering little solace to income investors.

Looking ahead, analysts project a potential recovery with an average EPS forecast of €4.44 for 2025. However, achieving this requires overcoming current headwinds. Recent analyst actions reflect caution; Jefferies & Company Inc. maintains a 'Hold' rating, and AlphaValue/Baader Europe has adjusted EPS expectations downward due to the possibility of a capital raise, which could dilute existing shares. Investors should closely watch the upcoming Q1 2025 results, expected around May 13, 2025, for clearer signs of the company's trajectory.

What is the current price trend for Bayer stock?

As of mid-April 2025, the stock traded around €20.76-€20.93. While showing very slight daily gains, it has experienced significant declines over the past month and year, trading far below its 52-week high.

What are Bayer's recent financial results?

Bayer reported a net loss per share of €0.34 for Q4 2024, a reversal from the profit seen in Q4 2023. Revenue also slightly decreased year-over-year.

What do analysts expect for Bayer in 2025?

Analysts forecast an average earnings per share (EPS) of €4.44 for 2025. However, recent performance and potential capital increases have led some analysts to express caution.

Do you think Bayer can meet the optimistic analyst expectations for 2025 despite the current pressures? Let us know!

*Share this article with others who need to stay ahead of this trend!*